Starlink to bring satellite network service to S. Korea
US Space firm SpaceX's Starlink satellite internet service is set to launch in South Korea following approval from government authorities last week. The rollout will mark the beginning of low Earth orbit, or LEO, satellite networks in the country, offering high-speed connectivity in remote and unreachable areas.
Seoul's Ministry of Science and ICT has approved the California-based company's cross-border supply agreement, along with similar deals involving Hanwha Systems and KT Sat, which are resellers of the UK-based Eutelsat-OneWeb, another low-orbit service provider.
In Korea, foreign companies are required to sign a supply agreement with domestic telecommunication operators to offer satellite services locally.
Starlink's local partner, SK Telink, said it plans to begin the service as soon as the final regulatory step is cleared — the conformity assessment of antennas it uses to receive satellite signals.
Unlike conventional mobile networks, where smartphones communicate directly with base stations on the ground, current LEO satellite communication services rely on antennas to receive signals from satellites.
The high-speed, low-latency internet service is expected to be particularly helpful for aircraft and maritime vessels, where internet access is limited.
'When low-orbit satellite telecommunication services launch in Korea, high-speed wifi networks will be available in airplanes and vessels," said ICT Minister Yoo Sang-im.
"For sailors on long voyages, the ability to stream video and make video calls will significantly improve life on board."
SK Telink said it will expand its product lineup to include maritime and aviation-specific packages, as well as packages for public institutions.
The company will also collaborate with local governments to build disaster-response communication networks in remote islands, mountainous regions and other areas where telecom infrastructure is difficult to establish, or where conventional networks are vulnerable during emergencies, the company said.
SpaceX launched its subsidiary Starlink Korea LLC here in 2023. Industry experts expect the service could begin as early as next month.
The commercialization of LEO satellite communications is also expected to accelerate the country's transition into the next-generation 6G era, experts say.
The 6G network is expected to significantly increase the number of connected devices per person. The advancement of autonomous vehicles, urban air mobility and virtual reality will require ultra-low latency and ultra-high-speed communication networks.
Satellite connectivity is also expected to supplement terrestrial infrastructure, helping to meet the surging demand for data.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
43 minutes ago
- Korea Herald
Lotte sets sights on global retail future at NRF Big Show
Lotte Shopping Vice Chair Kim Sang-hyun highlighted the group's global strategy and innovation efforts at NRF Big Show APAC 2025, held in Singapore from Tuesday to Thursday. The event, hosted by the National Retail Federation, a US-based retail trade association, was held for the first time in the Asia-Pacific region and drew 10,000 retail leaders, including Amazon. During a session titled 'Retail Transformation, The Lotte Story,' Kim spoke with Vipul Chawla, CEO of Singapore's FairPrice Group, about Lotte's evolving approach to customer-centered retail and digital transformation. Kim, who heads the Korean firm's retail division, introduced Lotte Mall West Lake Hanoi as a leading example of innovative customer experience. The mall, which opened in 2023, recorded over 200 billion won ($147 million) in cumulative sales within nine months and 10 million visitors within 354 days. He described it as a platform that goes beyond retail, connecting customers with culture and lifestyle. Addressing structural challenges in Korea, such as economic uncertainty and an aging population, Kim explained how Lotte is expanding into global markets and utilizing artificial intelligence-driven solutions. A key project includes the construction of an AI-powered customer fulfillment center in Busan, in partnership with Ocado, to enhance hyperpersonalized recommendations and logistics automation. Kim also introduced Lotte Mart Express, recently launched inside FairPrice's VivoCity location, as a case of successful collaboration. Looking to the next three to five years, Kim stressed the importance of creating value in customers' time and experience. 'Lotte will make a strong commitment toward global competitiveness through customer-centric and tech-driven innovation,' Kim said.
Korea Herald
3 hours ago
- Korea Herald
Trump's chip subsidy renegotiation casts uncertainty over Samsung, SK hynix
The Trump administration is renegotiating subsidies pledged under the previous Biden administration's CHIPS Act, sparking concerns that South Korean chipmakers Samsung Electronics and SK hynix might see cuts in funding for their US investments. US Commerce Secretary Howard Lutnick told the Senate Appropriations Committee that some of the subsidy agreements reached during the Biden administration 'just seemed overly generous, and we've been able to renegotiate them,' according to Reuters. 'All the deals are getting better, and the only deals that are not getting done are deals that should have never been done in the first place,' Lutnick was quoted as saying. His remarks suggest that not all grants pledged under the CHIPS Act will be paid out as originally committed, leaving chipmakers who were counting on the funding for their large-scale US projects in doubt. From the campaign trail, US President Donald Trump repeatedly called for the repeal of the subsidies, arguing that imposing tariffs, instead of grants, would be more effective to lure chipmakers to set up manufacturing facilities in the US. During an address to a joint session of the US Congress in March, Trump said the CHIPS Act is a 'horrible thing' and called for its removal. In 2022, then-US President Joe Biden signed the CHIPS and Science Act, allocating $39 billion in subsidies and grants for semiconductor companies setting up manufacturing and research facility in the US. Among the beneficiaries were chip heavyweights including Taiwan's TSMC, Korea's Samsung and SK hynix, as well as US-based Intel and Micron. Any delays or renegotiated terms for investment could deal a blow to Samsung and SK hynix, who had already pledged to invest tens of billions of dollars to build new advanced chip facilities. Depending on funding plans, they may be forced to reconsider their US investment strategies. Samsung is investing over $37 billion to build two new advanced fabrication plants and an R&D facility in Taylor, Texas. In return, the company has been awarded $4.74 billion in direct funding. SK hynix has secured $450 million in direct funding for a $3.87 million investment in building an advanced chip packaging plant and an R&D center in West Lafayette, Indiana. Regarding the future of their funding, a Samsung Electronics official said the company is monitoring the situation. An SK hynix official said there was nothing to comment on at this time.
Korea Herald
5 hours ago
- Korea Herald
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis —this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. "This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan, PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic." Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill. In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms. Visionary Founders Driving the Innovation Focal Medical was co-founded by: Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity. "After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers, Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers." This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy. About Continuity Biosciences Continuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL; Houston, TX; Raleigh, NC; and Torino, Italy, the company focuses on combination drug-device platforms for chronic and complex conditions. Visit:
